Business Context and Reporting Period
This Form 8-K was filed by NanoViricides, Inc. on April 18, 2011, reporting the entry into a Material Definitive Agreement. The Company, a Nevada corporation, entered into a Securities Purchase Agreement with Seaside 88, LP to raise capital through the sale of Series B Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of up to 500,000 shares of Series B Convertible Preferred Stock.
- Initial Closing (April 19, 2011): Seaside 88, LP purchased 250,000 shares.
- Gross Proceeds (Initial): $2,500,000.
- Estimated Offering Expenses: Approximately $200,000 (including placement agent and attorney fees).
- Net Proceeds (Initial): Approximately $2,300,000.
- Purchase Price: $10.00 per share of Series B Preferred Stock.
- Initial Conversion Price: $1.28138 per share of Common Stock.
- Placement Fee: 6% of the gross purchase price paid to Midtown Partners & Co., LLC.
Material Changes and Transaction Structure
The filing details a two-stage funding structure:
- Initial Closing: Completed on April 19, 2011, for 250,000 shares.
- Subsequent Closing: Scheduled for 14 weeks following the Initial Closing, contingent upon the Company satisfying conditions precedent. This closing involves the purchase of the remaining 250,000 shares for an additional $2,500,000.
The Series B Preferred Stock includes an automatic conversion mechanism. 40,000 shares convert into Common Stock at the Initial Closing, the Subsequent Closing, and every 14 days thereafter. The conversion price is calculated based on a discount to the Volume Weighted Average Price (VWAP) of the Common Stock, subject to a floor price of $0.20.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the anticipated subsequent closings. Management highlights the following risks and contingencies:
- Condition Precedents: The subsequent closing is not guaranteed and depends on the Company's ability to satisfy specific conditions.
- Dilution: The Company acknowledges substantial dilution to current stockholders due to the purchase price discount offered to Seaside.
- Market Overhang: Potential market pressure may arise from the resale of shares acquired by Seaside under the Agreement.
The filing does not provide specific revenue, profit, or cash flow metrics for the reporting period, as this is a current report focused on a specific financing event rather than a periodic financial statement.
Investor Verification Checklist
- Verify the Company's ability to satisfy the conditions precedent required for the Subsequent Closing.
- Monitor the Common Stock VWAP to calculate future conversion prices and assess potential dilution.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification terms.
- Assess the impact of the 6% placement fee and other offering expenses on the net capital raised.
- Check for any subsequent filings regarding the resale of shares by Seaside 88, LP.